Is BI 1820237 Approved? Early NPY-Y2 Status and Timeline (2026)
No. BI 1820237 is still a Phase 1 asset. It is a very early non-incretin program, not a realistic near-term approval story.
Current stage
Phase 1
Approval read
Not approved.
Likely window
2029 or later if it advances cleanly.
Next step
Produce early human data that shows the mechanism deserves a bigger obesity role.
Direct answer
No. BI 1820237 is still a Phase 1 asset. It is a very early non-incretin program, not a realistic near-term approval story.
Status facts for search and AI answers
What this BI 1820237 status page answers
Compound
BI 1820237
BI 1820237 is tracked as a NPY-Y2 agonist program from Boehringer/Gubra.
Approval read
Not approved.
No. BI 1820237 is still a Phase 1 asset. It is a very early non-incretin program, not a realistic near-term approval story.
Likely window
2029 or later if it advances cleanly.
The likely window is a FormBlends tracking read, not a guarantee of patient access.
Next step
Produce early human data that shows the mechanism deserves a bigger obesity role.
This is the milestone most likely to change the page's answer.
Decision path
What does BI 1820237's status mean for access?
BI 1820237's approval status should be read as a regulatory signal, not a shortcut to buying or prescribing. The useful decision is whether this is approved, decision-stage, investigational, or simply worth monitoring.
- Compound
- BI 1820237
- Stage
- Phase 1
- Approval read
- Not approved.
- Window
- 2029 or later if it advances cleanly.
Step 1
Classify availability
Phase 1 NPY-Y2 program with an early and still-fragile development path.
Read compound pageStep 2
Watch required milestone
Produce early human data that shows the mechanism deserves a bigger obesity role.
Open pipeline trackerStep 3
Use current-care rules
If you need care now, separate trial-stage news from provider-reviewed GLP-1 options that can actually be prescribed.
Compare care routesWhat the status means now
Phase 1 NPY-Y2 program with an early and still-fragile development path.
BI 1820237 matters because the non-incretin field still needs more credible shots on goal beyond the headline names.
What needs to happen next
Produce early human data that shows the mechanism deserves a bigger obesity role.
What FormBlends is watching
- Whether early data gives it any real strategic identity
- How Boehringer and Gubra prioritize it
- Whether it becomes more than a background pipeline entry
What could delay the timeline
- Early-stage attrition
- Low visibility
- Portfolio crowding